Jacobio Pharma Announces 2025 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025.

During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same period in 2024. Research and development (R&D) expenses amounted to  RMB93.2 million. The net loss for the first half of 2025 was RMB59.0 million,  narrowing by 65.1% compared with the same period in 2024. As of June 30, 2025, Jacobio maintained cash and bank balances, and investments in capital protected structure deposits, totaling RMB1,07billion, along with RMB270 million bank credit available which provides sufficient and stable liquidity to support our R&D activities.

Dr. Yinxiang Wang, Chairman and Chief Executive Officer of Jacobio, said: "In the first half of 2025, we reached an important milestone with the  approval and launch of Glecirasib in China. Through our collaboration with business partners, we significantly ...